Clinical Trials

MannKind Corporation is committed to the development of innovative pharmaceutical products that address significant unmet medical needs. In the development of those products, clinical trials are conducted to determine their safety and efficacy in order to be approved for use by patients.

MannKind has an ethical obligation to publish information about clinical trials for our own investigational products. We publish information on our clinical trials in scientific journals and participate in the clinical trials registry at www.clinicaltrials.gov. MannKind ensures ethical and safe conduct to protect all subjects in its clinical trials. MannKind posts protocol information for all Phase II and III MannKind-sponsored clinical studies.

Diabetes

AFREZZA™  MannKind has completed its Phase III clinical trials for AFREZZA, additional post marketing studies have been initiated. For more information or to enroll please visit www.clinicaltrials.gov

Cancer

MKC1106-MT is an active immunotherapy vaccine regimen that has completed a Phase 1 clinical trial in the United States for the treatment of advanced melanoma where the Melan-A and tyrosinase tumor associated antigens are frequently expressed.  For more information please visit www.clinicaltrials.gov

MKC1106-PP is an active immunotherapy vaccine regimen that has completed a Phase 1 clinical trial in the United States for the treatment of solid tumor malignancies where the PRAME and PSMA tumor associated antigens are frequently expressed.  For more information please visit www.clinicaltrials.gov